On this page
These two destinations take most of the world’s stem cell medical travel between them, and comparisons are usually written by someone selling one of them. Thailand and Mexico differ in regulation, in who travels where, and in what happens afterwards — and on the thing that matters most, the underlying evidence, they do not differ at all.
The comparison that does not exist
The evidence for any given treatment is identical in both countries. A trial conducted in Korea or Spain says exactly what it says regardless of where you fly to receive the intervention.
So no comparison of destinations can tell you whether a treatment works. It can only tell you about access, cost, oversight and logistics.
Anyone framing a country as the reason a treatment succeeds is selling geography — see what the evidence levels mean.
It follows that the useful comparison is between clinics rather than between countries, and that a good clinic in the weaker jurisdiction beats a poor one in the stronger.
Who actually goes where
Mexico draws overwhelmingly from the United States and Canada, for the obvious reason: Tijuana is a short drive from San Diego, and border clinics have built around that.
Thailand draws from Europe, Australia, the Middle East and Asia, alongside a substantial existing medical travel industry serving other specialties.
That difference in catchment shapes both markets. A clinic serving a drive-across market is organised differently from one serving patients on eleven-hour flights, and the follow-up problem is much larger in the second case.
It also shapes the marketing. Material aimed at a market where the treatment is prohibited tends to lean on that prohibition, which is a rhetorical advantage rather than a clinical one — see the United States comparison.
Regulation
Both countries regulate cell therapy, and in both the enforcement picture is more complicated than either “strictly controlled” or “anything goes”.
Mexico’s border clinic sector has attracted particular regulatory attention, partly because of its proximity to a market where the treatments are unavailable, and there have been enforcement actions.
Thailand has its own framework administered through the Thai FDA and Ministry of Public Health — see regulation in Thailand.
In both cases, what matters more than the national picture is whether the specific facility is licensed and the specific practitioner registered, and both are checkable independently.
A national regulatory reputation is an average across hundreds of providers. You are not buying the average, you are buying one clinic, and the distribution around that average is wide in both countries.
Cost
Broadly comparable, with wide variation within each country that swamps the difference between them.
Mexico can be cheaper for North Americans once travel is included, simply because the journey is shorter. For anyone flying from Europe or Australia that advantage disappears entirely.
In both countries, price varies by cell source, dose and number of treatments far more than by location — see the cost page. Two clinics on the same street can differ by a factor of three for reasons that have nothing to do with which street it is.
Medical infrastructure
Thailand has a large and long-established international medical sector, built over decades around cardiac surgery, orthopaedics and dentistry. Major private hospitals are internationally accredited and accustomed to foreign patients.
That matters specifically for complications. If something goes wrong, the question is what hospital care is available and how quickly, and a well-developed private hospital network is a genuine advantage.
Mexico also has excellent hospitals, particularly in the larger cities. The border clinic sector is a distinct thing from Mexican medicine generally, and conflating them is unfair to the latter — Mexican cardiology and oncology are not the border clinic sector, any more than Thai medicine is defined by whoever advertises hardest to foreigners.
Follow-up, where distance bites
Proximity is Mexico’s real advantage for North American patients. A complication two weeks later means a drive rather than a long-haul flight, and a review appointment is feasible rather than theoretical.
For European and Australian patients neither destination offers practical follow-up, which makes documentation and the willingness of a doctor at home to engage the deciding factors.
Ask both what follow-up they provide after you leave, and whether anyone will write to your own physician — see international patients.
What to compare instead of countries
The questions that actually separate providers are the same in both places, and none of them is geographical.
- Cell type, source, and autologous or allogeneic
- Dose, and which published trial that number comes from
- Where cells are processed, and what release testing is done
- Whether the facility is licensed and the practitioner registered
- What happens if assessment concludes you are unsuitable
- What follow-up exists after you fly home
A clinic in either country answering those precisely is a better prospect than one in the other country that does not — see safety studies.
An honest summary
For North Americans, Mexico’s proximity is a real and practical advantage, particularly for follow-up.
For everyone else, Thailand’s established medical travel infrastructure and hospital network are the stronger argument, and the flight is long from either direction.
Neither country makes an unproven treatment work, and the evidence pages here apply equally wherever you go — see the research library.
If you are weighing both, the most productive thing you can do is send the same records to a clinic in each and compare what comes back. Two assessments of the same imaging, read side by side, will tell you more about either clinic than any amount of comparison of the countries they sit in.
Frequently asked questions
Which country has better treatment?
Neither, in the sense that matters. The evidence for any given treatment is identical in both places — what differs is access, cost and logistics.
Is Mexico cheaper?
Often for North Americans once travel is counted. From Europe or Australia that advantage disappears, and within-country variation is larger than between-country.
Which is better regulated?
Both regulate cell therapy, and enforcement is complicated in both. What matters more is whether the specific facility and practitioner are licensed, which you can check.
What about complications?
Thailand’s established private hospital network is a genuine advantage there. Mexico’s proximity is the advantage for North Americans needing review.
How do I actually compare two clinics?
On cell type, dose, processing, release testing, licensing and follow-up. None of those questions is geographical.
Does going further mean better quality?
No. Distance is a logistics variable rather than a quality one, and treating it as a proxy for standards is a mistake in either direction.
Requesting a medical evaluation
Nothing on this page establishes whether any treatment is appropriate for you. That needs your history, your imaging and your current medications read by a clinician. If you would like that review, send your records and we will tell you honestly whether there is anything worth discussing — including when the answer is no.
This page is general information, not medical advice, and does not create a doctor–patient relationship. Regenerative treatments discussed here are in most cases investigational. Discuss any treatment with a clinician who knows your history.